neurofibromatosis type 2

(redirected from Neurofibromatosis type II)
Also found in: Wikipedia.

Neurofibromatosis type 2 (NF2)

A hereditary condition associated with an increased risk of bilateral acoustic neuromas, other nerve cell tumors and cataracts.
Mentioned in: Acoustic Neuroma
neurofibromatosis type 2 intercranial neoplasms and deafness
References in periodicals archive ?
In the United States, the ABI is approved for use only in patients 12 years or older with neurofibromatosis type II, an inherited disease that causes a non-malignant brain tumor on the hearing nerve, but it has shown limited effectiveness in adults.
Otoncurosyphilis masquerading as neurofibromatosis type II.
The Nucleus(R) 24 ABI, designed for those suffering from Neurofibromatosis Type II (NF2).
Donna Getz is a member of a family who has been dealing with the effects of neurofibromatosis type II (NF2) for several generations.
This investigational device is designed to activate hearing neurons with more precision than previous devices to improve speech recognition for patients suffering from a hereditary disease called Neurofibromatosis Type II (NF2).
These findings suggested the presence of schwannomas and led to a presumptive diagnosis of neurofibromatosis type II.
were the first to implant a pair of electrodes in the brainstem of a Neurofibromatosis Type II (NF2) patient during surgery to remove acoustic tumors.
Like the ABI, the PABI is designed for patients suffering from Neurofibromatosis Type II (NF2), a hereditary disease that can cause profound hearing loss through the growth of bilateral tumors on the vestibular nerves.
Agenesis of internal carotid artery associated with neurofibromatosis type II.
Cochlear Corporation announced today that the Food and Drug Administration (FDA) recently approved the Nucleus 24 Multichannel Auditory Brainstem Implant (Multichannel ABI) for use in patients suffering from Neurofibromatosis Type II (NF2), a genetic condition that affects one in 40,000 people in the United States.
The Food and Drug Administration (FDA) has approved Cochlear Corporation's Nucleus 24 [R] Multichannel Auditory Brainstem Implant (Multichannel ABI) for use in patients suffering from Neurofibromatosis Type II (NF2), a genetic condition that affects one in 40,000 people in the United States.